Research Topics
Genomes and GenesSpecies | Johan HanssonSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Adjuvant therapy of cutaneous melanoma -- current statusJohan Hansson
Acta Oncol 45:369-72. 2006- NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencingEsther Edlundh-Rose
Department of Gene Technology, School of Biotechnology, Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
Melanoma Res 16:471-8. 2006..7). In conclusion, the separate genotypes were associated with differences in several key clinical and pathological parameters, indicating differences in the biology of melanoma tumours with different proto-oncogene mutations... 
Familial melanomaJohan Hansson
Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital Solna, S 17176 Stockholm, Sweden
Surg Clin North Am 88:897-916, viii. 2008..Guidelines for management of familial melanoma and the issue of genetic testing for CDKN2A germline mutations are discussed...- Familial cutaneous melanomaJohan Hansson
Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital Solna S 171 76, Stockholm, Sweden
Adv Exp Med Biol 685:134-45. 2010..A much smaller number of families have germline mutations in the CDK4 gene on chromosome 12q14, encoding a cyclin dependent kinase which normally interacts with p16INK4A. The management of families with hereditary melanoma is discussed... 
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid
The Angeles Clinic and Research Institute, Santa Monica, USA
J Transl Med 9:204. 2011..The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab...- Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trialJohan Hansson
Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Lancet Oncol 12:144-52. 2011..We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma... - Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive programJohan Hansson
Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
J Clin Oncol 25:2819-24. 2007..To evaluate a program initiated in 1987 by the Swedish Melanoma Study Group aiming to provide preventive surveillance to kindreds with hereditary cutaneous melanoma and dysplastic nevus syndrome... - Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutationsMalihe Eskandarpour
Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Hospital and Karolinska Institute, Stockholm, Sweden
J Natl Cancer Inst 95:790-8. 2003..We investigated the occurrence of NRAS mutations in melanomas and dysplastic nevi in individuals with germline CDKN2A mutations... - MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parametersVeronica Höiom
Department of Oncology Pathology, CCK, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
Pigment Cell Melanoma Res 22:196-204. 2009..No association was found between CDKN2A gene variants and general melanoma risk. Two new variants in the POMC gene were identified in red haired individuals without RHC alleles... - High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanomaAnders Jonsson
Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet Karolinska University Hospital, Stockholm, Sweden
J Invest Dermatol 130:2809-17. 2010..Interestingly, p16(INK4A) promoter methylation was significantly overrepresented in NRAS-mutated samples compared to NRAS wild-type samples (P=0.0004), indicating an association between these two events... - NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progressionKatarina Omholt
Cancer Centre Karolinska, Department of Oncology Pathology, Radiumhemmet, Karolinska Hospital and Institute, Stockholm, Sweden
Clin Cancer Res 9:6483-8. 2003..Here, we have screened the same tumor samples for BRAF mutations... - Non-invasive and microinvasive electrical impedance spectra of skin cancer - a comparison between two techniquesPeter Aberg
Division of Medical Engineering, Karolinska Institutet, Huddinge, Sweden
Skin Res Technol 11:281-6. 2005.... - Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteAnton Platz
Department of Oncology Pathology, Karolinska Institute, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm S 17176, Sweden
Mol Oncol 1:395-405. 2008..Common alterations of the signal transducing network seem to represent molecular hallmarks of cutaneous melanomas and therefore should continue to strongly stimulate design and testing of targeted molecular interventions... - Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survivalEva Grafström
Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
Clin Cancer Res 11:2991-7. 2005..We have in the present study measured the frequency of INK4 deletions in a large number of melanoma metastases and determined their association with clinicopathologic variables and survival data... - The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanomaHildur Helgadottir
Department of Oncology Pathology, Karolinska Institute, Radiumhemmet, Karolinska University Hospital, 171 76, Stockholm, Sweden
Cancer Immunol Immunother 58:1599-608. 2009..1 [(A2) B15 Cw3 DRB1*04] in patients with stage III-IV serous ovarian cancer. The objective of the present study was to determine the role of the HLA phenotype on the prognosis in stage III-IV malignant melanoma patients... - Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanomaGiuseppe Valentino Masucci
Department of Oncology Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
Melanoma Res 16:357-63. 2006..Thrombocytopenia might be a positive predictive factor for response to therapy... - MicroRNA expression profiles associated with mutational status and survival in malignant melanomaStefano Caramuta
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
J Invest Dermatol 130:2062-70. 2010..The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice... - Mutations of PIK3CA are rare in cutaneous melanomaKatarina Omholt
Department of Oncology-Pathology, Cancer Centre Karolinska, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
Melanoma Res 16:197-200. 2006..Taken together, our results show that PIK3CA is mutated in a minority of melanomas and suggest that mutations in this gene may represent an alternative mechanism of Akt activation in cutaneous melanoma... - Family members' perceptions of genetic testing for malignant melanoma--a prospective interview studyMia Bergenmar
Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital, SE 17176 Stockholm, Sweden
Eur J Oncol Nurs 13:74-80. 2009..The aim was to prospectively explore experiences related to genetic testing for malignant melanoma among unaffected previously untested members of melanoma-prone families in which germline CDKN2A mutations had been identified... - Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitroMalihe Eskandarpour
Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
Int J Cancer 124:16-26. 2009..These studies support the concept that suppression of oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by modulating the levels of these gene products... - Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanomaC Christian Johansson
Department of Oncology and Pathology, Cancer Center Karolinska, R8 01, Karolinska University Hospital, Karolinska Institutet, 171 76 Stockholm, Sweden
Cancer Immunol Immunother 58:1085-94. 2009..The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma... - Germline CDKN2A mutations are rare in child and adolescent cutaneous melanomaPeter Berg
Department of Dermatology and Venereology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden
Melanoma Res 14:251-5. 2004..Thus, in the large majority of cutaneous melanoma in childhood/adolescence, any underlying genetic alterations have yet to be identified... - Implementing organisation and management innovations in Swedish healthcare: lessons from a comparison of 12 casesJohn Øvretveit
The Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
J Health Organ Manag 26:237-57. 2012.... - Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanomaBraslav Jovanovic
Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
J Invest Dermatol 128:2696-704. 2008..Immunohistochemical analysis of cytoplasmic phosphorylated ERK could be used as a prognostic marker in primary melanomas if confirmed in another data set... - Case study of how successful coordination was achieved between a mental health and social care service in SwedenJohan Hansson
LIME, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
Int J Health Plann Manage 27:e132-45. 2012..One lesson for the current policy is that, where full structural integration is not possible, then client-level coordination roles in each sector are useful to connect sector services for shared clients... - Genome-wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanomaVeronica Höiom
Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, S 171 76 Stockholm, Sweden
Genes Chromosomes Cancer 50:1076-84. 2011..01). Our data suggest that these chromosomal regions, 17p12-p11 in particular as it was present in both analyses, may harbor genes involved in the susceptibility of malignant melanoma in the Swedish population... - Simulation team training for improved teamwork in an intensive care unitChrister Sandahl
Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Int J Health Care Qual Assur 26:174-88. 2013..This study aims to describe implementation of simulator-based medical team training and the effect of this programme on inter-professional working in an intensive care unit (ICU)... - Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cellsMalihe Eskandarpour
Department of Oncology Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
Int J Cancer 115:65-73. 2005..These data suggest that oncogenic NRAS is important for avoidance of apoptosis in melanomas that harbor the codon 61 NRAS mutation and emphasizes oncogenic NRAS as a therapeutic target in patients with tumors that harbor this mutation... - Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-signIsabel Poschke
Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden
Cancer Res 70:4335-45. 2010..These results emphasize the diversity of MDSC in human cancer and provide potential targets for therapeutic interventions... - Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanomaMia Bergenmar
Department of Oncology Pathology, Karolinska Hospital and Institutet, Stockholm, Sweden
Acta Oncol 43:161-8. 2004.... - Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex)Boel Ragnarsson-Olding
Department of Oncology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden
Acta Oncol 44:773-7. 2005 - Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trialMia Bergenmar
Department of Oncology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Scand J Plast Reconstr Surg Hand Surg 44:146-55. 2010..No differences in health-related QoL or emotional distress were found between the two arms, indicating that resection margins have limited impact on these variables... - Hereditary uveal melanoma: a report of a germline mutation in BAP1Veronica Höiom
Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
Genes Chromosomes Cancer 52:378-84. 2013..Such individuals may then be enrolled in preventive programs and regular screenings to facilitate early detection and thereby improve prognosis... - Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencingMax Käller
Department of Biotechnology, The Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
Clin Chem 51:2388-91. 2005 - Context challenges the champion: improving hip fracture care in a Swedish university hospitalSusanne Löfgren
Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
Int J Health Care Qual Assur 25:118-33. 2012..The purpose of this paper is to describe and explain a clinician-led improvement of a hip fracture care process in a university hospital, and to assess the results and factors helping and hindering change implementation... - Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenograftsJessica Cedervall
Department of Woman and Child Health, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
Cancer Res 69:3746-54. 2009..In conclusion, these data provide exciting options for using the hEST model in molecular in vivo studies on differentiation, invasiveness, and malignancy of human melanoma, while analyzing species-specific reactions in vivo... - High-dose Cisplatin with amifostine: ototoxicity and pharmacokineticsAndreas Ekborn
Department of Otolaryngology Head and Neck Surgery, Karolinska Institute, Stockholm, Sweden
Laryngoscope 114:1660-7. 2004.... - KIT pathway alterations in mucosal melanomas of the vulva and other sitesKatarina Omholt
Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
Clin Cancer Res 17:3933-42. 2011.... - Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progressionKatarina Omholt
Cancer Centre Karolinska, Department of Oncology-Pathology, Radiumhemmet, Karolinska Hospital and Institute, Stockholm, Sweden
Clin Cancer Res 8:3468-74. 2002..This suggests that activated N-ras may be an attractive target for therapy in the subset of melanoma patients carrying such mutations... - Surgical treatment of skeletal metastases in 31 melanoma patientsRikard Wedin
Dept of Orthopaedics, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Acta Orthop Belg 78:246-53. 2012..This study represents the largest reported cohort surgically treated for skeletal metastasis of malignant melanoma at a single institution... - What happened to the no-wait hospital? A case study of implementation of operational plans for reduced waitsJohan Hansson
Department of Learning Informatics Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
Qual Manag Health Care 21:34-43. 2012..This article reports a case study of a hospital implementation of operational plans for reduced waits, with an emphasis on the process of change... - No evidence of RALGDS mutations in cutaneous melanomaKatarina Omholt
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
Melanoma Res 17:410-2. 2007 - Skin cancer identification using multifrequency electrical impedance--a potential screening toolPeter Aberg
Division of Medical Engineering, Karolinska Institutet, Novum Research Park, SE 14186 Huddinge, Sweden
IEEE Trans Biomed Eng 51:2097-102. 2004..The power of skin cancer detection using electrical impedance is as good as, or better than, conventional visual screening made by general practitioners... - An integrated health and social care organisation in Sweden: creation and structure of a unique local public health and social care systemJohn Øvretveit
The Medical Management Centre, Karolinska Institute, Sweden
Health Policy 97:113-21. 2010.... - Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriersTord Forsner
Department of Public Health Sciences, Karolinska Institutet, Stockholm SE 171 76, Sweden
BMC Psychiatry 10:8. 2010..The aim of this study was to determine perceived facilitators and barriers to guideline implementation and clinical compliance to guidelines for depression in psychiatric care... - A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARFJamileh Hashemi
Department of Oncology-Pathology, Research Laboratory of Radiumhemmet, Cancer Center Karolinska, R8:03, Karolinska Hospital, S-171 76 Stockholm, Sweden
Cancer Lett 180:211-21. 2002..This partial functional defect may complement the clearly defective p16 del (62-69) mutant and thus contribute to melanoma development in patients carrying the 24bp deletion in CDKN2A... - Melanoma cells produce multiple laminin isoforms and strongly migrate on α5 laminin(s) via several integrin receptorsYuko Oikawa
Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
Exp Cell Res 317:1119-33. 2011.... - FBXW7/hCDC4 is a general tumor suppressor in human cancerShahab Akhoondi
Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
Cancer Res 67:9006-12. 2007..Our study is the first comprehensive screen of FBXW7 mutations in various human malignancies and shows that FBXW7 is a general tumor suppressor in human cancer... - Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patientsPaola Ghiorzo
Department of Oncology, Biology, and Genetics, University of Genova, Genova, Italy
Hum Pathol 35:25-33. 2004.... - Localization of a novel melanoma susceptibility locus to 1p22Elizabeth Gillanders
Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD
Am J Hum Genet 73:301-13. 2003..43, was obtained at D1S2779 and occurred when the 15 families with the earliest ages at onset were included. These data provide significant evidence of a novel susceptibility gene for CMM located within chromosome band 1p22... - Genetic testing for melanomaRichard Kefford
Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, New South Wales, 2145, Australia
Lancet Oncol 3:653-4. 2002 - A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in womenMarit Bragelien Veierød
Section of Medical Statistics, University of Oslo, Oslo, Norway
J Natl Cancer Inst 95:1530-8. 2003..Here we report the first results from a large prospective cohort study of pigmentation factors and sun exposure in relation to melanoma risk... - Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factorsChrister Lindholm
Department of Oncology, County Hospital Ryhov, Jonkoping, Sweden
Cancer 101:2067-78. 2004.... - Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locationsPeter Gillgren
Department of Surgery, Stockholm Soder Hospital, SE 118 83 Stockholm, Sweden
Melanoma Res 15:125-32. 2005..It can be concluded that the tumour site is of prognostic importance, and that the middle and lower back and supramammary and mammary areas are independent factors related to a poor prognosis... - ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinomaDaniel F Gudbjartsson
deCODE Genetics, Sturlugata 8, 101 Reykjavik, Iceland
Nat Genet 40:886-91. 2008..14, P = 6.1 x 10(-4)). An eye color variant in TYRP1 was associated with risk of CM (OR = 1.15, P = 4.6 x 10(-4)). The association of all three variants is robust with respect to adjustment for the effect of pigmentation... - Common sequence variants on 20q11.22 confer melanoma susceptibilityKevin M Brown
Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona 85028, USA
Nat Genet 40:838-40. 2008..The per allele odds ratio was 1.75 (1.53, 2.01), with evidence for stronger association in early-onset cases... - High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMELAlisa M Goldstein
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
Cancer Res 66:9818-28. 2006..This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available... - The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanomaMicaela Hernberg
Department of Oncology, HUSLAB, Helsinki University Central Hospital, Finland
J Immunother 30:773-9. 2007..Our data show that both the proportions of CD3+CD4+CD69+ cells and of CD3+CD56+ cells seem to have a prognostic potential in the natural course of melanoma. These results need to be confirmed in larger studies... - Induction of melanoma phenotypes in human skin by growth factors and ultraviolet BCarola Berking
The Wistar Institute, Philadelphia, Pennsylvania, USA
Cancer Res 64:807-11. 2004..This is the first report on human cancer initiation in vivo in which an imbalance of physiological factors combined with an environmental carcinogen can lead to transformation of normal tissue... - Geographical variation in the penetrance of CDKN2A mutations for melanomaD Timothy Bishop
Genetic Epidemiology Division, Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, UK
J Natl Cancer Inst 94:894-903. 2002..We examined the penetrance of such mutations using data from eight groups from Europe, Australia and the United States that are part of The Melanoma Genetics Consortium... - Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastasesAsa Sivertsson
AlbaNova University Center, Department of Molecular Biotechnology, Royal Institute of Technology (KTH, S-106 91 Stockholm, Sweden
Clin Chem 48:2164-70. 2002..CONCLUSION: Pyrosequencing is an attractive alternative to SSCP analysis for N-ras mutation detection in malignant melanoma tumor samples because it displays the same sensitivity and accuracy as SSCP analysis and is simple and rapid... - Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVBJean Emeny
Department of Biochemistry, University of Leicester, United Kingdom
J Invest Dermatol 128:1875-7. 2008 - Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Mol Cancer Ther 7:2876-83. 2008.... - Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapyShuhua Ma
Department of Oncology/Pathology, Research Laboratory of Radiumhemmet, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
Oncol Rep 9:1015-9. 2002..However, there was no significant correlation of MMR expression alone or combined with MGMT levels with clinical response to DTIC-based chemotherapy in metastatic melanoma... - Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsAlisa M Goldstein
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
J Med Genet 44:99-106. 2007....